LONDON, Nov 6 (Reuters) - Novo Nordisk said

the side effects in trials so far for its experimental obesity

drug CagriSema were similar to its GLP-1 drugs already on the

market, and reiterated its expectation the new injection will

deliver 25% weight loss.

Martin Holst Lange, Novo Nordisk's head of development, made

the comments to Reuters in an interview after the company

released better-than-expected third-quarter results.

The Danish drugmaker is due to release data from a

late-stage trial of CagriSema, a two-drug combination obesity

treatment that like its popular obesity drug Wegovy is injected,

by the end of 2024.